Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
- Nov 18, 2015Clinical Study (MORAb-009-201) of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma (MPM)
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in the randomized, double-blind ARTEMIS—Amatuximab Research in Treatment-naïve Epithelial...
- Nov 17, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into an agreement with the Targeted Alpha Therapy Group (TAT Group) at the University of Gothenburg in Sweden to...
-
Nov 13, 2015
Helsinn Group and Eisai Inc. announced today that the American Society of Clinical Oncology (ASCO) has published a focused update to its clinical practice guidelines for antiemetics in oncology...
- Nov 9, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of Seattle, WA, a privately held biotechnology company...
- Oct 26, 2015
Eisai Inc. announced today that Halaven® (eribulin mesylate) Injection has been nominated by the Galien Foundation within the category, "Best Pharmaceutical Agent of the Year" at the ninth annual...
- Oct 26, 2015
Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive effects of the CA125 tumor antigen on the investigational...
-
Oct 19, 2015Findings suggest need for improved dialogue between patients receiving chemotherapy and their healthcare team, including pharmacists
-
Oct 16, 2015
Results from an investigational Phase 2 clinical trial evaluating lenvatinib in combination with everolimus and lenvatinib and everolimus alone for the treatment of metastatic renal cell carcinoma...
-
Oct 15, 2015
Eisai Inc. announced today the presentation of a company-record seven abstracts at the 15th International Thyroid Congress (ITC), highlighting the importance of the Phase 3 SELECT trial of...
-
Oct 8, 2015
Eisai Inc. announced the decision of the National Comprehensive Cancer Network® (NCCN®) to recommend LENVIMA™ (lenvatinib) as the preferred agent for the treatment of patients with progressive...
